Bioreactors Market Competitive Analysis Share & Forecast, 2022-2028| Coherent Market Insights

 

Bioreactors Market

A Bioreactor is a manufactured or engineered vessel used in the production of a variety of biological products. A biochemical process using microbes, animal cells, or biologically active substances derived from living cells is carried out in an industrial Bioreactor. The most crucial element in bioprocessing is the cylinder-shaped Bioreactor, which can hold volumes ranging from litres to cubic metres. In Bioreactors, fermentation procedures are carried out for the production of wine and beer. Stainless steel is used in Bioreactors that are used to produce therapeutic products on a large scale.

Small glass Bioreactors are used in biopharmaceutical companies for scale-up and research and development activities. Disposable Bioreactors, also known as single-use Bioreactors because they are designed for one use only, are another type of Bioreactor. It is typically employed for in-depth manufacturing and research. Batch, fed batch, and continuous stirred tank processes can all be used in Bioreactors. Therapeutics like monoclonal antibodies, vaccines, stem cells, and gene-modified cells are produced in Bioreactors.

Single-use Bioreactors are now more productive in terms of production, quality assurance, and procurement across the pharmaceutical industries. Single-use Bioreactors have several benefits that promote the growth of the Bioreactors Market, including consistency in production, increased manufacturing speed, decreased operational costs, and shorter manufacturing times for finished dosage forms. According to the National Centre for Biotechnology Information (NCBI), single-use Bioreactors have operational costs per gramme of monoclonal antibody production (mAb) that are about 22% lower than those of conventional systems in 2016. This difference is primarily attributable to lower labour, utility, maintenance, and waste costs.

Conventional fed-batch Bioreactors typically require 10000L - 25000L stainless steel tanks to culture cells and produce yields of 2–6 g/L for commercial-scale monoclonal antibody production (mAb). Single-use Bioreactors, on the other hand, produce 10–30 times more cells per unit volume and use continuous cell culture supply in 500–2000 litre tanks. As a result, more products can be produced using these single-use Bioreactors while occupying less space and spending less money. Low water usage by single-use systems, the need for less floor space, and the low risk of cross-contamination in single-use systems are other factors that support market expansion.

Furthermore, according to a case study published in 2016 by the Cambridge Healthtech Institute, using single-use (SU) Bioreactors can result in annual savings of US$ 60,000 in labour costs for setting up and cleaning stainless steel tanks as well as US$ 250,000 in water generation for injections. Over the anticipated period, these elements are anticipated to fuel market growth for Bioreactors. Additionally, the enzymes used in bioprocessing have a focused action and result in a pure product. Worldwide prevalence of illnesses like diabetes and anaemia—415 million people had diabetes in 2014, according to the World Health Organization (WHO)—indicates the need for increased bioprocessed product availability at faster rates, where advanced Bioreactors may be helpful.

Types of Bioreactors-

·        Stainless Steel Bioreactor

·        Glass Bioreactor

·        Single-Use Bioreactor

 

Major Companies listed are- Thermo Fisher Scientific, Inc., Merck KGaA, GE Healthcare, Pall Corporation, ZETA Holdings GmbH, Sartorius AG BBI, Solaris, Praj HiPurity Systems Limited, BiOENGiNEERiNG, INC., Infors AG, and Appplikon Biotechnology, Inc.